Vnitřní lékařství 2/2020

P Ř EHLEDOVÉ Č LÁNKY Diosmin/hesperidin – spolupracující tandem nebo je diosmin klí č ový a hesperidin jen neú č innou p ř ím ě sí? | 103 / Vnitř Lék 2020; 66(2): 97–103 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz Na otázku, zda kombinace diosmin/hesperidinová frakce je účinným tandemem či zda je hesperidin jen neúčinnou příměsí, lze odpovědět jednoznačně. Každý z flavonoidů má svůj farmakodynamický účinek a pouze pro kombinaci obou složek existují doklady o účinku. Jak dokládá též experimentální práce, kombinace jednotlivých složek flavonoidůmá, minimálně na úrovni antiexudativního působení, synergistický účinek (19). Rozhodně tak není možno souhlasit s tvrzením, že jedinou účinnou látkou je diosmin a ostatní flavonoidy jsou jen neúčinnou příměsí. LITERATURA 1. Ligi D, Croce L, Mannello F. Chronic venous disorders: The dangerous, the good, and the diverse. Int. J. Mol. Sci. 2018; 19: 2544, 2. Wittens C, et al. Management of Chronic Venous Disease. Clinical Practice Guide- lines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2015; 49: 678–737. 3. Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorde- rs of the lower limbs. Guidelines according to scientific evidence. Part I. Int Angiol 2018, June 37(3): 232–254. 4. Karetová D. Chronická žilní onemocnění končetin ve světle mezinárodních doporučení publikovaných v roce 2018 (Guidelines for the management of chronic venous disorde- rs of the lower limbs, Int Angiol, 2018), Postgraduální medicína 2019, ročník 21, č. 1: 52–57. 5. Ding Z, Sun G, Zhu Z. Hesperidin attenuates influenza A virus (H1N1)-induced lung injury in rats through its anti-inflammatory effect. Antivir Ther. 2018 Apr 6. doi: 10.3851, IMP3235. 6. Lee HJ, Im AR, Kim SM et al. The flavonoid hesperidin exerts anti-photoaging effect by downregulating matrix metalloproteinase (MMP)-9 expression via mitogen activated pro- tein kinase (MAPK)-dependent signaling pathways. BMC Complement Altern Med. 2018 Jan 30;18(1):39. doi: 10.1186/s12906-017-2058-8. 7. Tejada S, Pinya S, Martorell M et al. Potential anti-inflammatory effects of hesperidin from the genus Citrus. Curr Med Chem. 2017 Jul 18. doi: 10.2174/0929867324666170718104412 8. Parhiz H, Roohbakhsh A, Soltani F, et al. Antioxidant and anti-inflammatory proper- ties of the citrus flavonoids hesperidin and hesperetin: an updated review of their mo- lecular mechanisms and experimental models. Phytother Res. 2015 Mar;29(3): 323–331. doi: 10.1002/ptr.5256 9. Milenkovic D, Deval C, Dubray C, et al. Hesperidin displays relevant role in the nutrige- nomic effect of orange juice on blood leukocytes in human volunteers: a randomized controlled cross-over study. PLoS One. 2011; 6(11): e26669. 10. Salden BN, Troost FJ, de Groot E, et al. Randomized clinical trial on the efficacy of he- speridin 2S on validated cardiovascular biomarkers in healthy overweight individuals. Am J Clin Nutr. 2016 Dec;104(6): 1523–1533. 11. Haidari F, Heybar H, Jalali MT, et al. Hesperidin supplementation modulates inflamma- tory responses following myocardial infarction. J Am Coll Nutr. 2015; 34(3): 205–211. 12. Rizza S, Muniyappa R, Iantorno M, et al. Citrus polyphenol hesperidin stimulates pro- duction of nitric oxide in endothelial cells while improving endothelial function and re- ducing inflammatory markers in patients with metabolic syndrome. J Clin Endocrinol Metab. 2011; 96(5): E782–792. 13. Morand C, Dubray C, Milenkovic D, et al. Hesperidin contributes to the vascular pro- tective effects of orange juice: a randomized crossover study in healthy volunteers. Am J Clin Nutr. 2011; 93(1): 73–80. 14. Takase S, Pascarella L, Lerond L, Bergan JJ Schmid-Schonbein GW. Venous hyperten- sion, inflammation and valve remodeling. Eur. J. Vasc. Endovasc. Surg. 2004; 28: 484–493. 15. Das Gracas CDSM, Cyrino FZ, de Carvalho JJ, Blanc-Guillemaud V, Bouskela E. Protec- tive Effects of Micronized Purified Flavonoid Fraction (MPFF) on a Novel Experimental Model of Chronic Venous Hypertension. Eur. J. Vasc. Endovasc. Surg. 2018;55: 694–702. 16. Laurent R, Gilly R, Frileux C. Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg. Int. Angiol. 1988; 7: 39–43. 17. Efficacy and Safety of Diosmin 600 mg Versus Placebo on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs (EDEN), ClinicalTrials.gov Iden- tifier: NCT01532882. 18. Feldo M, Wójciak-Kosior M, Sowa I, et al. Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis. Molecules. 2019; 24(18): 3316. 19. Paysant J, Sansilvestri-Morel P, Bouskela E, et al. Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its anti- -hyperpermeability effect in the hamster cheek pouch microcirculation. Int Angiol. 2008; 27(1): 81–85. 20. Amato C. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in compa- rison with a nonmicronized diosmin. Angiology 1994; 45: 531–536. 21. Cospite M, Dominici A. Advantage of micronisation of Daflon 500 mg compared with a simple diosmine in the treatment of venous insufficiency. Double blind study. Phlebo- logie 1998; 51: 243–247. 22. Henriet J-P. Insuffisance veineuse fonctionnelle: essai clinique comparatif d’une se- ule prise par jour de Diovenor® 600 mg (600 mg de diosmine d’hémisynthèse) versus 2 prises par jour d’un mélange de 500 mg de flavonoides (900 mg de diosmine). Phlebo- logie 1995; 48: 285–290. 23. Clinical Non-inferiority Study Between Diosmin 600 mg & Diosmin + Hesperidin in Symptomatic Chronic Venous Insufficiency. ClinicalTrials.gov Identifier: NCT03471910. 24. Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Int Angiol. 37(3): 181–254. doi: 10.23736/S0392-9590.18.03999-8. 25. Jantet G. RELIEF study: first consolidated European data. Reflux assEssment and quaLity of lIfe improvement with micronized Flavonoids. Angiology 2000; 51: 31–37. 26. Bush R, Comerota A, Meissner M, Raffetto JD, Hahn SR, Freeman K. Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF). Phlebology 2017; 32 (1_suppl): 3–19. 27. Aziz Z, Huin WK, Badrul Hisham MD, Tang WL, Yaacob S. Efficacy and tolerability of micronized purified flavonoid fractions (MPFF) for haemorrhoids: A systematic review and meta-analysis. Complement Ther Med 2018; 39: 49–55. 28. Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic ve- nous disease: a systematic review and meta-analysis of randomized double-blind placebo- -controlled trials. Int Angiol 2018; 37: 143–154. 29. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjun- ctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg 2005; 30: 198–208. 30. Allaert FA. Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema. Int Angiol 2012; 31: 310–315. Dlouhodobě usilujeme o společensky odpovědný přístup k našemu podnikání. Důkazem je titul: Odpovědná firma roku 2019 Olomouckého kraje